Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof
US-9127053-B2 · Sep 8, 2015 · US
Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
US2015218217A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2015218217-A1 |
| Application number | US-201514610468-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jan 30, 2015 |
| Priority date | Jan 31, 2014 |
| Publication date | Aug 6, 2015 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making and using these polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic and prophylactic indications.
First claim
Opening claim text (preview).
What is claimed: 1 . An isolated polypeptide comprising a cleavable moiety (CM) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 269-273, 275-279, 281, 282, 284-286, 270-273, 2-5, 7-9, 11, 12, 14-17, 19, 20, 22-25, 27-30, 32-34, 36-39, 41-44, and 250-267, wherein the cleavable moiety is a substrate for a protease. 2 . The isolated polypeptide of claim 1 , wherein the CM comprises an amino acid sequence selected from the gr…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2015218217A1 cover?
- The invention relates generally to polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), to activatable antibodies and other larger molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and to methods of making…
- Who is the assignee on this patent?
- Cytomx Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K7/08. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Aug 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).